Clinical trials located in

Utrecht

Utrecht city is located in Netherlands. Currently, 20 clinical trials are being conducted in this city.

Utrecht, nestled in the heart of the Netherlands, boasts a rich history dating back to Roman times. This vibrant city is renowned for its picturesque canals with unique wharf cellars, now housing cafes and terraces by the water. Dominating the skyline, the iconic Dom Tower stands as the tallest church tower in the country. Utrecht is also a cultural hub, home to the Rietveld Schröder House, a UNESCO World Heritage site exemplifying De Stijl architecture. Furthermore, it’s a leading academic center with the prestigious Utrecht University attracting scholars worldwide.

  • CT-EU-00121101

    Stem cell transplantation vs. drugs for immunosuppression in early systemic scleroderma

    The clinical trial concerns patients diagnosed with early diffuse systemic sclerosis (dcSSc). This study will compare two treatment strategies: autologous hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy.

    Immunosuppressive therapy includes intravenous cyclophosphamide (CYC) followed by oral mycophenolate mofetil (MMF).

    The aim of the study is to determine which of these two methods is most effective in the treatment of early-stage systemic sclerosis in terms of survival and prevention of organ failure.

    Participation in this study is possible for patients aged 18 to 65 years with diagnosed systemic sclerosis. Patients are divided into two groups: one will receive HSCT immediately, the other will undergo immunosuppressive therapy, with HSCT being a rescue option if there is no response to treatment.

    Measuring effectiveness will be based on multiple health metrics, such as event-free survival, overall survival, disease progression, number of patients requiring rescue therapy, and health-related quality of life.

  • Comparison of Olorofim and AmBisome® for Treating Invasive Aspergillosis in Patients Who Cannot Use Azole Therapy

    This study focuses on patients dealing with a serious fungal infection called Invasive Aspergillosis (IA). This infection is known to be particularly dangerous for people with weakened immune systems. Two drugs will be compared in this study: Olorofim (also known as F901318) and AmBisome® (liposomal amphotericin B). These drugs are used to treat patients who have a confirmed or suspected IA infection.

    AmBisome® is an established treatment, while Olorofim is a newer medication that works differently. This new drug aims to provide an alternative for patients who don’t respond well to existing therapies.

    The purpose of this study is to compare the effectiveness and safety of Olorofim with AmBisome®, followed by standard care according to medical guidelines. Patients will receive one of the treatments, and their response will be monitored over several months.

    Patients will start with either Olorofim or AmBisome® for a set period, then switch to the standard care recommended by their doctors. This approach allows researchers to understand how well each treatment works and what side effects might occur.

    Participation includes regular follow-ups and assessments to monitor the patient’s health, response to the medication, and any potential side effects. The ultimate goal is to find the best possible treatment for IA, improving outcomes for patients affected by this serious fungal infection.

    • AmBisome®
    • olorofim
  • Study of JNJ-79635322 for Multiple Myeloma and Amyloidosis

    This study is investigating a new drug called JNJ-79635322, which is a trispecific antibody. The main goal of this study is to establish a recommended dose and schedule of drug administration that will be safe for participants. This medicine is intended for people with relapsed or refractory multiple myeloma or previously treated light chain (AL) amyloidosis.

    In the first part of the study, called dose escalation, doctors will gradually increase the dose of the medicine to find the highest dose that is well tolerated. In the second part, called dose expansion, the medicine will be administered at a previously established dose and doctors will monitor the safety and tolerability of the medicine in different groups of patients.

    JNJ-79635322 will be administered as a subcutaneous injection. During the study, doctors will carefully monitor any side effects and abnormal laboratory test results. The most important thing is to ensure the safety of participants and find the optimal dose of the drug.

    • JNJ-79635322
  • TolDCB29 dendritic cell therapy in the treatment of rheumatoid arthritis

    This study aims to evaluate a new treatment for people suffering from rheumatoid arthritis. The treatment involves taking parts of a person’s own immune cells, called dendritic cells, and filling them with a special protein called B29 peptide. This produces TolDCB29, which is then injected back into the body near the lymph nodes in the groin area.

    The main goal of this study is to determine whether TolDCB29 treatment is safe for patients with rheumatoid arthritis. Scientists also want to see if it can help train the immune system to stop attacking the body’s own body, which causes joint inflammation and damage in rheumatoid arthritis.

    The patient will receive two injections of TolDCB29 approximately four weeks apart. Study doctors will start by giving a low dose to a small group, then increase the dose to the next group until they find the highest safe dose. Patients will be closely monitored for any side effects or worsening of symptoms of rheumatoid arthritis.

    This study only includes adults over 18 years of age with rheumatoid arthritis that has been well controlled with current medications for at least 12 weeks. During the study, patients can continue to take their existing arthritis medications, except Janus kinase inhibitors.

    • autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70/TolDCB29
  • Study of asciminib dosing and safety in pediatric patients with Chronic Myeloid Leukemia

    This study is designed to determine the appropriate dosing and assess the safety of the drug asciminib for children and teenagers who have a specific type of leukemia called Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML-CP). These patients have previously been treated with at least one other medication known as a tyrosine kinase inhibitor (TKI). The study involves giving different doses of asciminib to see how well the drug works and how safe it is in young patients. The study will enroll participants into two age groups and will follow them over a five-year period to observe the effects of the treatment.

    • Asciminib
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    • Belzutifan
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    • Abemaciclib
    • Temozolomide
    • Irinotecan
    • Ramucirumab
    • Gemcitabine
    • Vinorelbine
    • Cyclophosphamide
    • Docetaxel
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Testing safety and tolerability of a new Amyotrophic Lateral Sclerosis medication

    This study aims to assess the safety and tolerability of a novel medication, designated as QRL-201, in individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS). The drug is administered via intrathecal administration, directly into the cerebrospinal fluid surrounding the spinal cord. The study comprises 64 participants divided into 8 groups. Within each group of 8 individuals, 6 will receive the active medication, while 2 will receive a placebo, a substance with no therapeutic effect. The investigation includes the monitoring and reporting of any observed side effects or serious health events. Additionally, assessments will be conducted to measure the peak concentration of the critical drug in the bloodstream, the time taken to reach this peak concentration, and the overall quantity of the drug present in the bloodstream.

    • QRL-201
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • A study of talquetamab in combination with other anticancer therapies for the treatment of Multiple Myeloma

    The study examines the efficacy and safety of a new drug, talquetamab, in combination with other medications: carfilzomib, daratumumab SC, lenalidomide, and pomalidomide, for the treatment of multiple myeloma, a type of blood cancer. Patients receive talquetamab with various drug combinations, aiming to improve treatment outcomes and understand the best therapeutic approach for this challenging blood cancer. The trial’s focus is on enhancing life quality for patients by exploring innovative combination therapies.

    • Daratumumab SC
    • Carfilzomib
    • Pomalidomide
    • Talquetamab
    • Lenalidomide
  • Emapalumab treatment study for patients with Macrophage Activation Syndrome

    This study is a test of a medicine called emapalumab on children and adults who have a condition called Macrophage Activation Syndrome (MAS), found in diseases like Still’s Disease or Systemic Lupus Erythematous. People who have not gotten better with high doses of a treatment called glucocorticoids may benefit from this study. The scientists want to understand if this medicine is safe, doesn’t cause too much discomfort, and if it works. The research will be done in two groups of people: Group 1 includes those with MAS from Still’s Disease, and Group 2 includes those with MAS from Systemic Lupus Erythematous. Scientists will track how the medicine behaves in the body, and the quality of life in these groups, for up to 1 year after the last dose of emapalumab.

    • Emapalumab
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    • Anticoagulation with heparin
  • Ponatinib treatment for children with various advanced cancers

    This trial focuses on a drug called ponatinib, that is being studied for the treatment of children (aged 1-18) with different harsh illnesses such as leukemias, lymphomas, and solid tumors. The researchers want to understand how safe the drug is, how well it works, and what happens to the drug in the body. Researchers will monitor any side effects that occur within the first 28 days of taking ponatinib. The researchers will also check if the drug is helping to reduce the illness by checking if there are fewer cancer cells in the body. The effects of the drug on the tumor will be monitored through scans like CT or MRI.

    • Ponatinib
  • Exploring the effectiveness and safety of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia treatment

    This study aims to investigate the efficacy of a new treatment called tisagenlecleucel in helping children and young adults combat B-cell Acute Lymphoblastic Leukemia (B-ALL), a high-risk form of blood cancer. The research is conducted across multiple hospitals and involves several stages, including eligibility assessments, treatment preparation, treatment administration, regular check-ups to monitor progress, and long-term follow-up. After receiving tisagenlecleucel, patients will have more frequent hospital visits in the initial month, followed by regular visits every few months for the first two years, and then annually until the study concludes, approximately eight years after the first patient undergoes treatment.

    • Tisagenlecleucel/CTL019
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    • Pemigatinib
    • Gemcitabine
    • Cisplatin

See more clinical trials in other cities in Netherlands:

.